Which option is most likely to fit you

A practical way to sort the options is by goal rather than brand. Across the current evidence base, these injections are mainly used to reduce pain and improve function in knee osteoarthritis rather than to cure it.

• Hyaluronic acid (HA) usually fits best as a symptom-control step when exercise, pain relief, or other conservative measures have not been enough and a non-surgical option is still preferred. CMS frames HA as a shared decision after other interventions have failed or been exhausted.
• PRP has comparatively strong review-level evidence for symptom improvement in early-to-moderate knee OA. A 2025 meta-analysis of 18 randomised trials found benefit over placebo, and a 42-study meta-analysis found better medium-term pain relief than HA or corticosteroid injections. The caution is that PRP protocols vary between clinics, and platelet concentration appears to matter.
• Arthrosamid is usually considered for selected patients with diagnosed knee OA — often mild-to-moderate disease, ongoing symptoms despite conservative care, and a wish to delay surgery. Published 52-week follow-up and official company reports of benefit out to 4 years support it as a longer-lasting single-injection hydrogel option, but that longer-acting approach needs a proper trade-off discussion.

In practice, the best fit usually comes down to five things: the main treatment goal, the strength of evidence, tolerance for uncertainty, expected recovery pattern, and what a suitable UK specialist actually offers.

When Arthrosamid is worth asking about

Arthrosamid tends to become relevant only at a fairly specific point in the pathway. Clinic guidance from London Cartilage Clinic and Cromwell Hospital places it in people with confirmed knee osteoarthritis who still have troublesome symptoms after conservative treatment, often with mild-to-moderate cartilage wear rather than advanced "bone-on-bone" change, and who are hoping to put off surgery. Its practical difference from hyaluronic acid or PRP is the format: a single polyacrylamide hydrogel injection intended to remain in the joint, rather than a repeat-series treatment.

Availability is clearer than candidacy. Contura says Arthrosamid was approved in Europe in 2020. In the UK, access is mainly through private specialists rather than routine NHS funding, and a 2025 company announcement described rollout across the Pure Sports Medicine network in London and the South East. Canada is further along too, with Health Canada approval announced in 2024 and launch in 2025. In the US, no primary FDA confirmation is cited here, so access is best treated as unconfirmed rather than assumed.

That long-lasting design is also the main trade-off. Because the hydrogel stays in the knee, the consent discussion needs to cover not just standard injection risks but also the implications of using a longer-lasting product. In practice, Arthrosamid is most worth discussing when the appeal of one longer-acting injection outweighs that different risk profile.

How to think about hyaluronic acid

For hyaluronic acid, the practical decision is often less about the label "gel injection" and more about the exact product being proposed. HA is a viscosupplement used for symptom relief rather than cartilage repair, and CMS places it in shared decision-making when exercise-based care, analgesics, weight management and other non-operative steps have not given enough benefit. In the published review evidence, formulations range from 1 injection to weekly courses of 3 or 5, but longer series have not shown a consistent outcome advantage simply because they involve more injections.

Logistics and expectations matter as much as the molecule. Benefit is often described as delayed rather than immediate, with HSS noting that it may take several weeks to work, although timing can vary. HSS also notes that allergy history may matter because some HA products are avian-derived. Funding rules can shape the plan too: CMS materials indicate that repeat viscosupplementation generally requires at least 6 months since the prior series, and insurers may define a covered "series" according to the product label.

Useful consultation questions include:

• the brand or formulation being used, and why that product was chosen
• whether the plan is 1 injection or a 3- or 5-injection series
• what recovery is usually like after each injection, including whether normal activity is limited for a day or two
• whether bird allergy or other allergy history changes the choice
• whether prior authorisation, insurer preference, or the 6-month repeat-series rule affects timing or cost

What makes PRP harder to judge

The awkward part of PRP in 2025 is that two clinics can both offer “PRP” and still mean different things. That matters because the overall evidence is encouraging: a 2025 meta-analysis of 18 randomised placebo-controlled trials found PRP superior to placebo, and a separate review of 42 studies suggested better medium-term pain relief than hyaluronic acid and corticosteroid injections, with the clearest advantage around 6 months and effects reported up to 12 months. Even so, those headline results do not automatically transfer to every protocol.

What varies in practice is the actual recipe and schedule. Clinics may differ in platelet concentration, whether the preparation is described as leukocyte-poor or leukocyte-rich, how the blood is processed or activated, and whether treatment is given as 1 injection or a short series. The 2025 meta-analysis specifically found that platelet concentration influenced outcomes, which helps explain why PRP is harder to judge than a fixed branded product.

Useful points to pin down in a consultation include:

• what type of PRP is being used, and how the clinic describes it
• whether the plan is 1 injection or a course, and why that schedule was chosen
• what published evidence the clinic relies on for that exact protocol
• what the first 1 to 2 weeks usually feel like after injection
• whether anti-inflammatory medicines need to be paused around treatment

Recovery is often a slower-burn story. AAOS says the knee may hurt more for the first week or two after PRP, and it may take several weeks before benefit is felt; HSS similarly notes that anti-inflammatory medicines are usually stopped around treatment because PRP relies on an inflammatory healing response. In plain language, that makes PRP a different discussion from cortisone: PRP is more often weighed for a potentially more sustained medium-term response than for rapid flare control.

When relief may start and how long it may last

Timing and durability are different questions. An injection may start to help within weeks yet fade sooner, or it may be slower to declare itself and last longer once it does. Across these three options, that distinction matters more than any simple “fastest” or “longest” label.

Arthrosamid is the clearest example of the slow-burn versus long-persistence trade-off. In an open-label study of 49 people given a single 6 mL injection, pain and function improvements were maintained through 52 weeks; the manufacturer also cites sustained pain relief and improved function out to 4 years. Even so, duration may vary from one knee to another.

With hyaluronic acid, there is no single universal timetable. HSS describes the benefit as delayed rather than immediate, often building over several weeks rather than the first few days. The exact timeline can still vary.

PRP is also usually judged over weeks to months, not overnight. AAOS says the knee may feel more sore for the first 1 to 2 weeks, and benefit may take several weeks to appear. In pooled comparative data, the clearest gains were seen around 6 months, with effects reported up to 12 months. Those headline timelines are only loosely comparable across clinics unless the product, dose, number of injections and follow-up window are similar.

What to ask before you choose a specialist

A strong knee OA injection consultation usually settles five points before treatment day: why this option fits the current stage of osteoarthritis, what evidence the clinician relies on, which alternatives still sit on the table, which risks matter in this knee, and how success will be measured at follow-up.

• Arthrosamid®: why a more permanent hydrogel approach is being proposed, and what the plan would be if relief is only partial or if surgery later needs discussing.
• Hyaluronic acid: the exact brand, whether treatment is a single visit or a defined series, any allergy or insurer issues, and what counts as a covered “series”; CMS materials note that repeat viscosupplementation is generally not considered before 6 months.
• PRP: how the blood is prepared, how many injections are planned, and what the first 1 to 2 weeks commonly feel like; AAOS and HSS note early soreness and that anti-inflammatory medicines are often paused.

One final question matters across all three: if the injection does not work well enough, when would the clinician repeat it, switch strategy, or move the conversation towards surgery? In practice, the best fit is usually the treatment that matches the knee, the goal and the specialist’s experience rather than the most heavily marketed product. Directory tools can help patients compare specialists by region and specialty.